A randomized, double-blind, placebo controlled, stage III clinical trial evaluated the efficacy and safety profile of adalimumab being a monotherapy in sufferers with RA who experienced unsuccessful to reply to csDMARDs [191]. The final results confirmed both statistically substantial advancement while in the illness activity and an excellent prote